首页> 外国专利> Phenyl-pyridinium salts and use thereof in inhibiting intestinal resorption

Phenyl-pyridinium salts and use thereof in inhibiting intestinal resorption

机译:苯基吡啶鎓盐及其在抑制肠道吸收中的用途

摘要

Polycyclic salts of the formula ##EQU1## wherein A.sup.- is the anion of a strong organic or inorganic acid;PPXN.sup.+ is pyridinium, pyrimidinium, thiazolium or imidazolium substituted by R. sup. 1, R.sup.2 and R.sup.3 ;PPn, q and r individually are the integer 1 or 0 and p is an integer from 1 to 15;PP Y is CH. sub.2, C(H,OH) or C(O):PPZ is O, S, CH.sub.2, C(O), NQ. sup.1, SO.sub.2, C(O)O, OC(O), C(O)N(Q.sup.1) or N(Q.sup.1)C(O); P PL is p-phenylene substituted by R.sup.4 ; andP PM is phenyl substituted by R.sup.5 and R.sup.6,PP T has one of the meanings given above, for Z or is C(CH.sub.3).sub.2, C. sub.2 H.sub. 4, C(Q.sup.2)C(Q.sup.3), C.tbd.C, CH.sub.2 C(O), C(O) CH.sub.2, CH. sub.2 O or OCH.sub.2,PPR.sup.1 is a group Ar, Ar-C.sub.1- 4 -alkyl, ArO or ArC(O),PPAr is phenyl substituted by R. sup.7, R.sup.8 and R.sup.9 ;PPR.sup.2 and R.sup.3 individually are H, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy or C. sub.6 H.sub. 5,PPwith the proviso that the N-atom in the 3-position of an imidazolium group XN.sup.+ is substituted by Ar,P PAr-C. sub.1-4 -alkyl or C.sub.1-4 -alkyl,PPR.sup. 4, R.sup.5, R. sup.6, R.sup.7, R.sup.8 and R.sup.9 individually are H, halogen, CF.sub.3, NO.sub.2, CN, C.sub.1-4 - -(alkyl, alkoxy, alkylthio or alkylsulphonyl), SO.sub.2 N(R,Q), C(O)N(Q.sup.4,Q.sup.5), C(O)Q.sup.4, C(O)OQ.sup.4 or OC(O)Q.sup.4,PPR, Q, Q.sup.1, Q.sup.2 and Q.sup.3 individually are H orPPC.sub.1-4 -alkyl, and P PQ.sup.4 and Q.sup.5 individually are C.sub.1-4 -alkyl inhibit the intestinal resorption of cholesterol and of bile salts in the enterohepatic circulation. These salts containing a quaternary N-atom can be manufactured starting from corresponding amines.
机译:式## EQU1 ##的多环盐,其中A-是强有机酸或无机酸的阴离子;-P X X N +是被R取代的吡啶鎓,嘧啶鎓,噻唑鎓或咪唑鎓。一口在图1中,R.sup.2和R.sup.3;

n,q和r分别是整数1或0,p是1到15的整数;

Y是CH。 sub.2,C(H,OH)或C(O):

Z是O,S,CH.sub.2,C(O),NQ。 sup.1,SO.sub.2,C(O)O,OC(O),C(O)N(Q.sup.1)或N(Q.sup.1)C(O);

L是被R.4取代的对亚苯基;并且

M是被R.sup.5和R.sup.6取代的苯基,

T具有对于Z的上述含义之一或为C(CH.sub.3 ).sub.2,C.sub.2 H.sub。 4,C(Q.sup.2)C(Q.sup.3),C.tbd.C,CH.sub.2 C(O),C(O)CH.sub.2,CH。 sub.2 O或OCH.sub.2,

P> Rups.1是基团Ar,Ar-C1-4烷基,ArO或ArC(O),

< P> Ar是被R.sup.7,R.sup.8和R.sup.9取代的苯基;

P> R.sup.2和R.sup.3分别是H,C。 1-4-烷基,C 1-4-烷氧基或C.sub。6H。 5,P

,条件是咪唑基团XNsup。+的3-位上的N原子被Ar,P

Ar-C取代。亚1-4烷基或C 1-4烷基,在图4中,R 5,R 6,R 7,R 8和R 9分别是H,卤素,CF 3,NO 2,CN ,C.sub.1-4-(烷基,烷氧基,烷硫基或烷基磺酰基),SO.sub.2 N(R,Q),C(O)N(Q.sup.4,Q.sup.5) ,C(O)Q.sup.4,C(O)OQ.sup.4或OC(O)Q.sup.4,

R,Q,Q.sup.1,Q.sup .2和Q 3分别是H或P C C 1-4-烷基,而P P Q 4和Q 5分别是C。亚1-4烷基抑制肠肝循环中胆固醇和胆汁盐的肠吸收。这些包含季氮原子的盐可以从相应的胺开始制备。

著录项

  • 公开/公告号US4675328A

    专利类型

  • 公开/公告日1987-06-23

    原文格式PDF

  • 申请/专利权人 HOFFMANN-LAROCHE INC.;

    申请/专利号US19860819187

  • 申请日1986-01-15

  • 分类号C07D211/72;C07D213/69;C07D211/84;C07D213/78;

  • 国家 US

  • 入库时间 2022-08-22 07:09:04

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号